Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
暂无分享,去创建一个
Walter Curran | Luis Souhami | B. Scheithauer | E. Shaw | W. Curran | D. Brachman | J. Buckner | M. Mehta | K. Fink | R. Jenkins | L. Souhami | G. Cairncross | B. Berkey | David Brachman | Minesh Mehta | Robert Jenkins | Karen Fink | Bernd Scheithauer | Brian Berkey | Gregory Cairncross | Jan Buckner | Edward Shaw | Normand Laperierre | N. Laperierre
[1] D. Louis,et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.
[2] B. Scheithauer,et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G S Bauman,et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. , 2000, International journal of radiation oncology, biology, physics.
[4] N. Mackworth,et al. Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores , 1992, Journal of Neuro-Oncology.
[5] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[6] M. J. van den Bent,et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features , 2003, Cancer.
[7] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] O. Chinot,et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] K. Hoang-Xuan,et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] G. Reifenberger,et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. , 1994, The American journal of pathology.
[11] D P Byar,et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.
[12] David N Louis,et al. Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro‐Oncology , 2003, Journal of neuropathology and experimental neurology.
[13] D. Louis,et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. , 1996, Journal of neurosurgery.
[14] D. Horsman,et al. Loss of Heterozygosity for Loci on Chromosome Arms 1p and 10q in Oligodendroglial Tumors: Relationship to Outcome and Chemosensitivity , 2003, Journal of Neuro-Oncology.
[15] R A Betensky,et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] M. Prados,et al. Anaplastic Oligodendrogliomas: Prognostic Factors for Tumor Recurrence and Survival , 2003, Oncology.
[17] G. Barnett,et al. Impact of Chromosome 1p Status in Response of Oligodendroglioma to Temozolomide: Preliminary Results , 2003, Journal of Neuro-Oncology.
[18] M. Taphoorn,et al. First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma , 2005 .
[19] L. Deangelis,et al. Brain Tumors , 2019, Imaging Gliomas After Treatment.
[20] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[21] J. Cairncross,et al. Successful chemotherapy for recurrent malignant oligodendroglioma , 1988, Annals of neurology.
[22] T. Cascino,et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Menten,et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Cairncross,et al. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma , 1990, Annals of neurology.